Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Transformed B-cell Lymphoma : Clonal Evolution, Microenvironment Remodeling and Therapeutic Targets Discovery; Prospective Program (TYPHON-P)

13 novembre 2026 mis à jour par: Julien BROSÉUS, Central Hospital, Nancy, France

The progression of small B-cell lymphomas toward a more aggressive histological form, specifically, diffuse large B-cell lymphoma (DLBCL) is a serious and most often fatal event. This process gives rise to several categories of scientific challenges :

  1. Anticipating this transformation through the early detection-while the disease is still in its indolent B-cell lymphoma stage-of biological markers that predict such a shift, particularly those that define tumor sub-clones at high risk of transformation.
  2. Identifying the specific event(s) that, within an ongoing and continuous process, trigger the definitive transition from the indolent B-cell lymphoma phase to the transformed B-cell lymphoma phase.
  3. Identifying the disrupted biological functions that drive treatment resistance in the transformed B-cell lymphoma stage, with the goal of defining new therapeutic targets.

Hypothesis :

  1. The aggressive transformation of indolent B-cell lymphomas results from an imbalance in the subclonal structure, driven by the evolution of a dominant subclone that undergoes aggressive transformation. This subclonal competition-occurring either spontaneously or under therapeutic pressure-is fueled by the acquisition and/or selection of specific molecular and epigenetic alterations, as well as favorable remodeling of the tumor microenvironment. Some of these changes are detectable as early as the indolent phase, offering the prospect of early detection, while others dictate the mechanisms of therapeutic resistance following transformation.
  2. Understanding the mechanisms of therapeutic resistance in transformed DLBCL could pave the way for the development of new, effective treatments. Furthermore, these insights could potentially be applied to resistant forms of de novo DLBCL-the most common category (40%) of B-cell lymphoma.

Our primary objective is to identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of de novo DLBCL.

Secondary objective 1. To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.

Secondary objective 2. To develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.

Secondary objective 3. To identify biological characteristic, at the indolent B-cell lymphoma stag, that are predictive of aggressive transformation.

Aperçu de l'étude

Description détaillée

TYPHON-P is a regional, multicenter, longitudinal, and translational observational study based on the prospectivebuilding of a clinical-biological cohort and a centralized biobank, managed by the Lorraine Biological Resource Center and the Pathology Department of the Nancy University Hospital. The study will include patients with indolent B-cell lymphoma, transformed B-cell lymphoma, or de novo aggressive B-cell lymphoma, as well as patients for whom a non-tumor tissue sample is available to serve as a technical reference.

Clinical, biological, therapeutic, and outcome data will be collected from medical records, and residual tissue samples originally obtained for routine clinical care will be processed according to standardized pre-analytical procedures and stored for future analysis.

The program comprises three complementary analytical sub-studies:

(i) a longitudinal, paired study comparing samples from the same patient at both the indolent and transformed stages, with the aim of characterizing the mechanisms of transformation; (ii) an investigation into the association between biological characteristics and therapeutic response within various groups of transformed B-cell lymphomas, with an exploration of whether these associations can be extrapolated to de novo diffuse large B-cell lymphoma (the most common lymphoma subtype, 15% of which exhibit therapeutic resistance); (iii) a prognostic study using samples obtained at the indolent stage to identify biological characteristics associated with the subsequent risk of transformation.

Analyses will be conducted separately for each lymphoma subtype, with Richter transformation and transformed follicular lymphoma serving as the primary models, while rarer forms will be the subject of exploratory analyses. Initial discovery-phase analyses will primarily relie on available retrospective samples. The identified biological findings and signatures will subsequently be evaluated within the prospective collection, following a pre-specified validation strategy. Longitudinal follow-up, planned for a maximum duration of ten years, will serve to document disease transformation, treatments received, therapeutic response, progression, and survival. Prospective samples will undergo standardized processing in a fresh state-including, wherever possible, the preparation of viable cell suspensions-to facilitate multi-omic, single-cell, spatial, and functional analyses, as well as the development of patient-derived models.

Type d'étude

Observationnel

Inscription (Estimé)

710

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Nancy, France, 54000
        • University Hospital of Nancy
        • Contact:

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Enfant
  • Adulte
  • Adulte plus âgé

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

Méthode d'échantillonnage

Échantillon non probabiliste

Population étudiée

The objective is to obtain a cohort of approximately 20 to 60 analyzable cases for each subtype of transformed B-cell lymphoma, enabling the exploration of molecular alterations associated with transformation, the study of mechanisms of therapeutic resistance, and the identification of biological signatures with theranostic relevance.

For technical and methodological reasons, a control group consisting of 20 non-tumor lymph node samples will be included in this study.

Recruitment objectives:

Recruitment target for the study group: 210 patients with transformed B-cell lymphoma

Recruitment targets for the 3 control subgroups:

  • 210 patients for the group with untransformed indolent B-cell lymphoma
  • 270 patients for the group with de novo diffuse large B-cell lymphoma
  • 20 patients for the control group

La description

Case groups: transformed B-cell lymphomas

Inclusion Criteria:

Patients who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

-with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma: CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

Patients in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup (including a tumor biopsy with histopathological analysis) is underway:

Richter transformation (RT) Transformed follicular lymphoma (tFL) Transformed marginal zone lymphoma (tMZL) Transformed lymphoplasmacytic lymphoma (tLPL) Blastoid mantle cell lymphoma

  • Cases subsequently confirmed as one of the following histological variants: DLBCL (Diffuse Large B-Cell Lymphoma), Hodgkin lymphoma, or blastoid variant
  • Cases for which biological samples potentially containing tumor cells are available and confirmed to contain a significant proportion of tumor cells (> 30%)
  • Patients for whom at least one of the following types of samples is available:

Circulating blood cells, plasma, serum, any sample of cerebrospinal fluid, pleural fluid, or peritoneal fluid, biopsies performed for the diagnosis and follow-up of the lymphoma, cells extracted from these biopsies

Exclusion Criteria:

  • Samples that do not meet the required diagnostic criteria
  • Samples that do not meet the quality criteria necessary for analysis
  • Samples that lack sufficient tumor content/representativeness for the requirements and analytical standards involved

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Modèles d'observation: COHORT
  • Perspectives temporelles: PROSPECTIVE

Cohortes et interventions

Groupe / Cohorte
Intervention / Traitement
Case group : Transformed B-cell lymphoma

Patients :

- who benefited from medical care at the University Hospital of Nancy or the Regional Hospital of Metz

Patients with a history of, or a current diagnosis of, one of the following five types of indolent B-cell lymphoma:

CLL: chronic lymphocytic leukemia FL: follicular lymphoma MZL: marginal zone lymphoma LPL: lymphoplasmacytic lymphoma MCL: mantle cell lymphoma

  • in whom an aggressive B-cell lymphoma is suspected and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway: RT: Richter transformation tFL: transformed follicular Lymphoma tMZL: transformed marginal zone lymphoma tLPL: transformed lymphoplasmacytic lymphoma BL-MCL: blastoid mantle cell lymphoma
  • cases subsequently confirmed as one of the following histological variants: Diffuse large B-cell lymphoma, Hodgkin lymphoma, or a blastoid variant

Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

De novo aggressive lymphoma group (primarily de novo DLBCL)

Patients:

- who benefited from medical care at the Nancy University Hospital or the Metz-Thionville Regional Hospital.

Patients in whom a de novo aggressive B-cell lymphoma (DLBCL, Hodgkin lymphoma, or a blastoid variant) is suspected, and for whom a diagnostic workup-including a tumor biopsy with histopathological analysis-is currently underway

  • with no prior history or concurrent diagnosis of a small B-cell lymphoma
  • for whom biological samples are available and confirmed to contain an adequate proportion of tumor cells (> 30%) These samples will be collected either as part of the diagnostic workupor during the course of follow-up

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

Indolent/small-cell non-transformed B-cell lymphomas group

Patients :

  • who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital
  • presenting with an indolent B-cell lymphoma, still untransformed at the corresponding index date, with a documented follow-up duration at least equal to the time interval between the diagnosis of the indolent lymphoma and the transformation observed in the transformed cases
  • for whom biological samples potentially containing tumor cells are available and contain an adequate proportion of tumor cells (> 30%) These samples will be collected either during the diagnostic work-up or during the course of follow-up

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Non-tumor patient" control group / lymph node tissue and blood free of tumor cells

Patients:

  • who benefited from medical care at the Nancy University Hospital or the Metz Regional Hospital
  • for whom one or more blood samples, serous fluid samples, and/or lymph node samples are available (either collected for suspected lymphoma or exploratory purposes, such as sentinel lymph node in solid-tumor oncology)
  • for whom the hypothesis of lymphoma or metastasis of solid cancer has been ruled out based on anatomopathological analysis (non-tumor samples)

Identification of molecular and/or cellular signatures associated with the type of treatment response in patients with transformed B-cell lymphoma-categorized as good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease)-defined in a discovery cohort and subsequently validated in an independent cohort, with an assessment of effect size, reproducibility, and discriminative value.

Performance of biological signatures, measured at the indolent stage, in predicting aggressive histological transformation during follow-up. This analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma. Biological associations will be characterized by their effect size, their statistical significance-following correction for multiple comparisons-and their reproducibility in a validation cohort.

Presence/absence of these molecular and/or cellular signatures correlated with therapeutic response in de novo DLBCL, and correlation with therapeutic response within this group.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
To identify and validate the molecular, cellular, and microenvironmental alterations associated with therapeutic resistance in transformed B-cell lymphomas, and to investigate the presence of these mechanisms in resistant forms of *de novo* DLBCLs
Délai: 10 years

Outcome measure 1 : correlation between gene expression profiles at agressive stage, and response to treatment.

Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : transcripts rates Outcome measure 2 : correlation between protein expression profiles at agressive stage, and response to treatment.

Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein Outcome measure 3 : correlation between tumor microenvironment, and response to treatment.

Measurement : microenvironment profiling by flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-cells, CD8+ T-cells, macrophages) Treatment responses : good responders (complete remission), partial responders, and non-responders (progression during treatment or primary refractory disease).

Signatures will be defined in a discovery cohort and subsequently confirmed in an independent cohort.

10 years

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Identify, at the indolent/small-cell B-cell lymphoma stage, the biological characteristics that are predictive of aggressive transformation.
Délai: 10 years

The analysis will be conducted separately for each homogeneous subgroup of transformed B-cell lymphoma.

Outcome measure 1 : correlation between gene expression profiles at indolent stage, and the occurence of agressive transformation.

Measurement : whole transcriptome profiling Measurement tool : RNA-sequencing Unit of measure : transcripts rates

Outcome measure 2 : correlation between DNA methylation profiles at indolent stage, and the occurence of agressive transformation.

Measurement : whole methylome profiling Measurement tool : long read whole genome sequencing Unit of measure : methylation rates for 28 billion sites

Outcome measure 3 : correlation between proteomic profiles at indolent stage, and the occurence of agressive transformation.

Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : absolute numbers for each protein

10 years
Develop cellular and animal models that mimic the transformed phase of indolent B-cell lymphomas.
Délai: 10 years

Outcome measure 1 : gene expression profiles concordance between patient-derived experimental models and the original tumors.

Measurement : whole transcriptome profiling by RNA-sequencing Unit of measure : rate of transcripts

Outcome measure 2 : protein expression profiles concordance between patient-derived experimental models and the original tumors.

Measurement : protein expression by liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein

Outcome measure 3 : tumor microenvironment profiles concordance between patient-derived experimental models and the original tumors.

Measurement : microenvironment profiling by flow cytometry or immunohistochemistry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

10 years
To understand the mechanisms underlying tumor evolution in each subtype of transformed B-cell lymphoma, with regard to both the characteristics of the tumor cell and its microenvironment.
Délai: 10 years

Outcome measure 1 : modification of gene expressions in malignant cells between the indolent stage, and the agressive transformation.

Measurement : gene expression Measurement tool : whole transcriptome sequencing (RNA-seq) Unit of measure : transcripts rates

Outcome measure 2 : modification of protein expressions in malignant cells between the indolent stage, and the agressive transformation.

Measurement : protein expression Measurement tool : liquid chromatography coupled with mass spectrometry Unit of measure : copy numbers for each protein

Outcome measure 3 : modification of tumor microenvironment between the indolent stage, and the agressive transformation.

Measurement : microenvironment profiling Measurement tool : flow cytometry Unit of measure : comparative enrichment for each immune cell subtype (CD4+ T-lymphocytes, CD8+ T-lymphocytes, CD25+ T-lymphocytes, macrophages)

10 years

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

1 décembre 2036

Achèvement de l'étude (Estimé)

1 décembre 2036

Dates d'inscription aux études

Première soumission

10 novembre 2026

Première soumission répondant aux critères de contrôle qualité

13 novembre 2026

Première publication (Réel)

19 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

19 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

13 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 2024PI145

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Anonymized samples and clinical data will be shared with companion research teams.

Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

Délai de partage IPD

Start date : inclusion date end date : end of the study (decembre 2036)

Critères d'accès au partage IPD

Material and/or data transfer agreements will be signed between the University hopital of Nancy (promoter) and the associated research teams.

Data will be transfered with secured transfer protocols.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • CIF
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner